{"id":"vehicle-topical-ocular-eye-drops","safety":{"commonSideEffects":[{"rate":"null","effect":"Eye irritation"}]},"_chembl":{"chemblId":"CHEMBL2108661","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Vehicle topical ocular eye drops are designed to improve the solubility and stability of other medications, enabling them to be administered in a more effective and targeted manner. This can enhance the bioavailability of the active ingredient and reduce systemic side effects.","oneSentence":"Vehicle topical ocular eye drops act as a carrier for other medications, allowing them to be delivered directly to the eye.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:40:23.265Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of dry eye disease"}]},"trialDetails":[{"nctId":"NCT04499248","phase":"PHASE1, PHASE2","title":"AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension","status":"RECRUITING","sponsor":"AbbVie","startDate":"2020-11-16","conditions":"Open-angle Glaucoma, Ocular Hypertension","enrollment":96},{"nctId":"NCT07128628","phase":"PHASE2","title":"A Study Evaluating the Safety and Efficacy of a Fixed-Dose Combination for Dry Eye Disease","status":"RECRUITING","sponsor":"Bausch & Lomb Incorporated","startDate":"2025-10-24","conditions":"Dry Eye Disease","enrollment":423},{"nctId":"NCT07412496","phase":"PHASE2","title":"A Study to Evaluate the Use of Topical Ocular BL1332 for the Management of Postoperative Ocular Pain Following Photorefractive Keratectomy","status":"NOT_YET_RECRUITING","sponsor":"Bausch & Lomb Incorporated","startDate":"2026-04","conditions":"Pain, Postoperative","enrollment":123},{"nctId":"NCT06919081","phase":"PHASE2","title":"Efficacy of Topical Mesenchymal Stromal Cell Secretome for Ocular Surface Disease","status":"RECRUITING","sponsor":"University of Illinois at Chicago","startDate":"2025-08-01","conditions":"Persistent Corneal Epithelial Defect, Corneal Epithelial Disorders","enrollment":24},{"nctId":"NCT06978244","phase":"PHASE1","title":"A Study to Assess Safety, Tolerability, and Pharmacokinetics of Ascending Concentrations of Topical Ocular BL1332 in Healthy Volunteers","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bausch & Lomb Incorporated","startDate":"2025-07-29","conditions":"Ocular Pain","enrollment":24},{"nctId":"NCT03918915","phase":"PHASE3","title":"The Safety and Efficacy of SYD-101 in Children With Myopia","status":"COMPLETED","sponsor":"Sydnexis, Inc.","startDate":"2019-04-24","conditions":"Nearsightedness, Near Sightedness, Near-sightedness","enrollment":852},{"nctId":"NCT05066997","phase":"PHASE2, PHASE3","title":"A Pivotal Safety and Efficacy Study of OCS-01 Eye Drops in Participants With Diabetic Macular Edema (DIAMOND 1)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Oculis","startDate":"2021-10-19","conditions":"Diabetic Macular Edema","enrollment":552},{"nctId":"NCT06172257","phase":"PHASE3","title":"A Pivotal Safety and Efficacy Study of OCS-01 Eye Drops in Participants With Diabetic Macular Edema (DIAMOND 2)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Oculis","startDate":"2024-03-15","conditions":"Diabetic Macular Edema","enrollment":401},{"nctId":"NCT07234318","phase":"","title":"Non-interventional Study to Evaluate the Anti-inflammatory Effects and the Clinical Efficacy of Topical Water Free Cyclosporin 0.1% Eye Drops in Patients With Dry Eye Disease and Associated Ocular Surface Inflammation Non-responding to Artificial Tears","status":"NOT_YET_RECRUITING","sponsor":"Laboratoires Thea","startDate":"2025-12-15","conditions":"Dry Eye Disease (DED)","enrollment":25},{"nctId":"NCT04638660","phase":"PHASE3","title":"Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) in Subjects With Dim Light Vision Disturbances","status":"COMPLETED","sponsor":"Ocuphire Pharma, Inc.","startDate":"2020-12-30","conditions":"Dim Light Vision Disturbances","enrollment":144},{"nctId":"NCT05486728","phase":"PHASE2","title":"Phase II Study of SHJ002 Sterile Ophthalmic Solution Compared With Vehicle in Participants With Dry Eye Disease","status":"COMPLETED","sponsor":"Dreamhawk Vision Biotech, Inc.","startDate":"2023-02-08","conditions":"Dry Eye Disease","enrollment":85},{"nctId":"NCT04675151","phase":"PHASE2","title":"Safety and Efficacy of Nyxol With Pilocarpine Eye Drops in Subjects With Presbyopia","status":"COMPLETED","sponsor":"Ocuphire Pharma, Inc.","startDate":"2021-02-15","conditions":"Presbyopia","enrollment":150},{"nctId":"NCT07109609","phase":"PHASE2","title":"Topical Menthol For Tear Secretion","status":"ENROLLING_BY_INVITATION","sponsor":"Reinhold Vieth","startDate":"2025-08-17","conditions":"Healthy, Dry Eyes","enrollment":30},{"nctId":"NCT07164092","phase":"PHASE2, PHASE3","title":"Efficacy of Topical Atropine Eye Drops for Control of Myopia Progression Among Children Attending Mansoura University Ophthalmic Center","status":"NOT_YET_RECRUITING","sponsor":"Mansoura University","startDate":"2025-09","conditions":"Myopia","enrollment":45},{"nctId":"NCT06381986","phase":"PHASE2","title":"Efficacy and Safety of SHJ002 Ophthalmic Solution in the Treatment of Corneal Erosion in Sjogren's Patients","status":"COMPLETED","sponsor":"Sunhawk Vision Biotech, Inc.","startDate":"2024-06-28","conditions":"Corneal Erosion","enrollment":116},{"nctId":"NCT05493111","phase":"PHASE3","title":"A Long-Term Safety Study Evaluating the Safety and Systemic Exposure of AR-15512","status":"COMPLETED","sponsor":"Aerie Pharmaceuticals","startDate":"2022-11-01","conditions":"Dry Eye Disease","enrollment":275},{"nctId":"NCT05135286","phase":"PHASE3","title":"Safety and Efficacy Study of BRIMOCHOL™ PF and Carbachol PF in Subjects With Emmetropic Phakic and Pseudophakic Presbyopia","status":"COMPLETED","sponsor":"Visus Therapeutics","startDate":"2022-03-15","conditions":"Presbyopia","enrollment":629},{"nctId":"NCT05360966","phase":"PHASE3","title":"Study Evaluating the Safety and Efficacy of AR-15512 (COMET-3)","status":"COMPLETED","sponsor":"Aerie Pharmaceuticals","startDate":"2022-07-18","conditions":"Dry Eye Disease","enrollment":467},{"nctId":"NCT05285644","phase":"PHASE3","title":"Study Evaluating the Safety and Efficacy of AR-15512","status":"COMPLETED","sponsor":"Aerie Pharmaceuticals","startDate":"2022-05-09","conditions":"Dry Eye Disease","enrollment":465},{"nctId":"NCT05896670","phase":"PHASE2","title":"Safety and Efficacy of Licaminlimab Ophthalmic Solution for the Treatment of Dry Eye Disease","status":"COMPLETED","sponsor":"Oculis","startDate":"2023-11-29","conditions":"Dry Eye Disease","enrollment":122},{"nctId":"NCT06164743","phase":"PHASE2","title":"Phase 2: VVN461 Ophthalmic Solution for Post -Operative Ocular Inflammation After Cataract Surgery","status":"COMPLETED","sponsor":"VivaVision Biotech, Inc","startDate":"2024-01-11","conditions":"Inflammation","enrollment":91},{"nctId":"NCT04734210","phase":"PHASE2","title":"Research Study To See How Well An Eye Drop (SURF-200) Works, What Side Effects There Are, And To Compare It With Vehicle In Subjects With An Episodic Flare-Up of Dry Eye Disease","status":"COMPLETED","sponsor":"Surface Ophthalmics, Inc.","startDate":"2021-01-07","conditions":"Dry Eye Disease","enrollment":139},{"nctId":"NCT04030962","phase":"PHASE1, PHASE2","title":"A Study of the Drugs AGN-242428 and AGN-231868 in Participants With Dry Eye Disease","status":"COMPLETED","sponsor":"AbbVie","startDate":"2020-03-04","conditions":"Dry Eye Disease, Dry Eye Syndrome","enrollment":292},{"nctId":"NCT06903611","phase":"PHASE3","title":"Phase III Study of Topical Fibrinogen-Depleted Human Platelet Lysate Compared to Placebo for Moderate to Severe Dry Eye","status":"NOT_YET_RECRUITING","sponsor":"Cambium Bio Limited","startDate":"2025-09-30","conditions":"Dry Eye Disease, Dry Eye, Dry Eyes Chronic","enrollment":400},{"nctId":"NCT04734197","phase":"PHASE2","title":"A Research Study To See How Well an Eye Drop, SURF-100 (A Mycophenolic Acid/Betamethasone Sodium Phosphate Combination), Works and What Side Effects There Are in Subjects With Dry Eye Disease","status":"COMPLETED","sponsor":"Surface Ophthalmics, Inc.","startDate":"2021-01-11","conditions":"Dry Eye Disease","enrollment":349},{"nctId":"NCT01331005","phase":"PHASE2","title":"NSAID Phase II for Non-central Involved Diabetic Macular Edema (DME)","status":"COMPLETED","sponsor":"Jaeb Center for Health Research","startDate":"2011-05","conditions":"Diabetic Macular Edema","enrollment":125},{"nctId":"NCT04097730","phase":"PHASE3","title":"Steroids and Cross-linking for Ulcer Treatment","status":"COMPLETED","sponsor":"Thomas M. Lietman","startDate":"2020-09-24","conditions":"Keratitis Bacterial","enrollment":280},{"nctId":"NCT04391894","phase":"PHASE2","title":"A Study to Assess the Safety and Efficacy of ECF843 vs Vehicle in Subjects With Dry Eye Disease","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2020-10-06","conditions":"Dry Eye","enrollment":718},{"nctId":"NCT04324359","phase":"PHASE2","title":"Study to See How Well an Eye Drop, SURF-201, Works and What Side Effects There Are in Cataract Surgery Subjects","status":"COMPLETED","sponsor":"Surface Ophthalmics, Inc.","startDate":"2020-03-03","conditions":"Post-surgical Ocular Inflammation, Post-surgical Ocular Pain","enrollment":91},{"nctId":"NCT06128369","phase":"PHASE3","title":"Study Evaluating the Efficacy and Safety of OCS-01 Eye Drops in Subjects Following Cataract Surgery","status":"TERMINATED","sponsor":"Oculis","startDate":"2023-12-18","conditions":"Inflammation Eye, Pain, Postoperative, Cataract","enrollment":117},{"nctId":"NCT04829344","phase":"PHASE3","title":"A Study of the Safety and Anesthetic Effect of AG-920 Topical Ophthalmic Solution","status":"COMPLETED","sponsor":"American Genomics, LLC","startDate":"2021-03-30","conditions":"Anesthesia, Local","enrollment":120},{"nctId":"NCT04498182","phase":"PHASE2","title":"A Phase 2b Study Evaluating the Safety and Efficacy of AR-15512 Ophthalmic Solution for the Treatment of Dry Eye Disease","status":"COMPLETED","sponsor":"Aerie Pharmaceuticals","startDate":"2020-10-26","conditions":"Dry Eye Disease","enrollment":369},{"nctId":"NCT05695781","phase":"PHASE3","title":"Assessment of the Safety and Efficacy of BRM421 Ophthalmic Solutions in Dry Eye Subjects.","status":"COMPLETED","sponsor":"BRIM Biotechnology Inc.","startDate":"2023-02-27","conditions":"Dry Eye Disease","enrollment":740},{"nctId":"NCT04806503","phase":"PHASE2","title":"A Dose-ranging Study to Evaluate the Safety and Efficacy of UNR844 in Subjects With Presbyopia.","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-06-30","conditions":"Presbyopia","enrollment":234},{"nctId":"NCT05848128","phase":"PHASE3","title":"Efficacy and Safety Evaluation of Tavilermide Ophthalmic Solution for the Treatment of Dry Eye","status":"COMPLETED","sponsor":"Mimetogen Pharmaceuticals USA, Inc.","startDate":"2023-06-28","conditions":"Dry Eye Syndromes, Dry Eye Disease, Kerato Conjunctivitis Sicca","enrollment":642},{"nctId":"NCT06348602","phase":"PHASE1, PHASE2","title":"Evaluation of Safety & Efficacy for the Prevention of Ocular GVHD With Ophthalmic Tacrolimus vs Cyclosporine in Allo-HSCT","status":"RECRUITING","sponsor":"Hospital Universitario Dr. Jose E. Gonzalez","startDate":"2023-08-01","conditions":"Ocular Graft-versus-host Disease","enrollment":60},{"nctId":"NCT03334539","phase":"PHASE2","title":"A Study to Assess Efficacy of HL036 in Subjects With Dry Eyes","status":"COMPLETED","sponsor":"HanAll BioPharma Co., Ltd.","startDate":"2017-11-05","conditions":"Dry Eye","enrollment":150},{"nctId":"NCT04004507","phase":"PHASE2","title":"Single Dose Study of Phentolamine Mesylate Eye Drops in Patients With Severe Night Vision Disturbances","status":"COMPLETED","sponsor":"Ocuphire Pharma, Inc.","startDate":"2007-08","conditions":"Decrease in Night Vision, Disturbance; Vision, Loss","enrollment":24},{"nctId":"NCT04403763","phase":"PHASE1, PHASE2","title":"Phase 1/2 Study of AGN-241622 in Healthy Participants and Participants With Presbyopia","status":"TERMINATED","sponsor":"AbbVie","startDate":"2020-07-27","conditions":"Presbyopia","enrollment":80},{"nctId":"NCT05109702","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of Tanfanercept (HL036) Ophthalmic Solution in Participants With Dry Eye","status":"COMPLETED","sponsor":"HanAll BioPharma Co., Ltd.","startDate":"2021-11-18","conditions":"Dry Eye","enrollment":260},{"nctId":"NCT04523142","phase":"PHASE3","title":"CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease in Subjects Who Completed CYS-004","status":"COMPLETED","sponsor":"Novaliq GmbH","startDate":"2021-01-04","conditions":"Dry Eye Disease (DED)","enrollment":202},{"nctId":"NCT03960866","phase":"PHASE2","title":"Safety and Efficacy of Ophthalmic Phentolamine Mesylate in Glaucoma","status":"COMPLETED","sponsor":"Ocuphire Pharma, Inc.","startDate":"2019-05-28","conditions":"Open Angle Glaucoma, Ocular Hypertension","enrollment":39},{"nctId":"NCT04620213","phase":"PHASE3","title":"Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis","status":"COMPLETED","sponsor":"Ocuphire Pharma, Inc.","startDate":"2020-11-18","conditions":"Mydriasis, Dilation","enrollment":185},{"nctId":"NCT03691649","phase":"PHASE3","title":"A Phase III Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Glaucoma or Ocular Hypertension - Spectrum 3 Study","status":"COMPLETED","sponsor":"Santen Inc.","startDate":"2018-09-14","conditions":"Glaucoma and Ocular Hypertension","enrollment":426},{"nctId":"NCT04024891","phase":"PHASE2","title":"Safety and Efficacy of Ophthalmic Phentolamine Mesylate to Reverse Pharmacologically Induced Mydriasis","status":"COMPLETED","sponsor":"Ocuphire Pharma, Inc.","startDate":"2019-08-13","conditions":"Mydriasis, Dilation","enrollment":32},{"nctId":"NCT05995392","phase":"EARLY_PHASE1","title":"The Effects and Safety of Topical Spironolactone Ophthalmic Solution, 0.005 mg/cc in Subjects With Dry Eye Disease","status":"UNKNOWN","sponsor":"Richard W Yee, MD","startDate":"2023-08","conditions":"Dry Eye Disease","enrollment":30},{"nctId":"NCT03691662","phase":"PHASE3","title":"A Phase III Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Glaucoma or Ocular Hypertension - Spectrum 4 Study","status":"COMPLETED","sponsor":"Santen Inc.","startDate":"2018-09-27","conditions":"Glaucoma and Ocular Hypertension","enrollment":417},{"nctId":"NCT03925727","phase":"PHASE3","title":"Tavilermide Ophthalmic Solution for the Treatment of Dry Eye","status":"COMPLETED","sponsor":"Mimetogen Pharmaceuticals USA, Inc.","startDate":"2019-03-28","conditions":"Keratoconjunctivitis Sicca, Dry Eye","enrollment":623},{"nctId":"NCT04523129","phase":"PHASE3","title":"ESSENCE 2: CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)","status":"COMPLETED","sponsor":"Novaliq GmbH","startDate":"2020-12-05","conditions":"Dry Eye Disease","enrollment":834},{"nctId":"NCT04620135","phase":"PHASE3","title":"Efficacy and Safety Study of Netarsudil 0.02% Ophthalmic Solution Compared to Ripasudil Hydrochloride Hydrate 0.4% Ophthalmic Solution in Japanese Subjects With Primary Open Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Aerie Pharmaceuticals","startDate":"2020-11-30","conditions":"Primary Open Angle Glaucoma, Ocular Hypertension","enrollment":245},{"nctId":"NCT05677945","phase":"NA","title":"3Mixtatin Versus Modified 3Mix-MP in Lesion Sterilization and Tissue Repair for Treatment of Necrotic Primary Molars","status":"UNKNOWN","sponsor":"Cairo University","startDate":"2023-03","conditions":"Necrotic Primary Molars","enrollment":24},{"nctId":"NCT03292809","phase":"PHASE2, PHASE3","title":"CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)","status":"COMPLETED","sponsor":"Novaliq GmbH","startDate":"2017-10-19","conditions":"Dry Eye Disease","enrollment":328},{"nctId":"NCT04513652","phase":"PHASE3","title":"A Study of the Safety and Anesthetic Effect of AG-920 Topical Ophthalmic Solution","status":"COMPLETED","sponsor":"American Genomics, LLC","startDate":"2020-09-03","conditions":"Anesthesia, Local","enrollment":120},{"nctId":"NCT03889886","phase":"PHASE2","title":"Study to Evaluate the Safety and Efficacy of SDP-4 in Subjects With Dry Eye Disease (DED)","status":"COMPLETED","sponsor":"Silk Technologies, Ltd.","startDate":"2019-04-16","conditions":"Dry Eye","enrollment":305},{"nctId":"NCT04535947","phase":"PHASE2","title":"Study to Evaluate the Efficacy of SDP-4 in Subjects With Dry Eye Disease (DED) (SDP-4-CS202)","status":"COMPLETED","sponsor":"Silk Technologies, Ltd.","startDate":"2020-08-14","conditions":"Dry Eye","enrollment":153},{"nctId":"NCT03809611","phase":"PHASE2","title":"A Study of Safety and Efficacy of UNR844 Chloride (UNR844-Cl) Eye Drops in Subjects With Presbyopia.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2019-04-26","conditions":"Presbyopia","enrollment":125},{"nctId":"NCT03846453","phase":"PHASE3","title":"A Study to Assess Efficacy and Safety of HL036 in Subjects With Dry Eyes","status":"COMPLETED","sponsor":"HanAll BioPharma Co., Ltd.","startDate":"2019-03-10","conditions":"Dry Eye","enrollment":637},{"nctId":"NCT05241145","phase":"PHASE1, PHASE2","title":"Safety and Preliminary Efficacy of IVMED-80 Eye Drops in Keratoconus Patients","status":"COMPLETED","sponsor":"iVeena Delivery Systems, Inc.","startDate":"2019-02-08","conditions":"Keratoconus, Corneal Ectasia","enrollment":38},{"nctId":"NCT02693119","phase":"PHASE2","title":"A Study Investigating the Safety, Tolerability, and Efficacy of Elamipretide Topical Ophthalmic Solution for Treatment of Leber's Hereditary Optic Neuropathy","status":"COMPLETED","sponsor":"Stealth BioTherapeutics Inc.","startDate":"2016-03","conditions":"Leber's Hereditary Optic Neuropathy","enrollment":12},{"nctId":"NCT04343287","phase":"PHASE2, PHASE3","title":"Safety and Efficacy of BRM421 for Dry Eye Syndrome Treatment","status":"COMPLETED","sponsor":"BRIM Biotechnology Inc.","startDate":"2020-01-15","conditions":"Dry Eye Syndrome","enrollment":220},{"nctId":"NCT02961062","phase":"PHASE2","title":"Study of SAF312 as an Eye Drop for Treatment of Eye Pain Following Photorefractive Keratectomy (PRK) Surgery","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2016-12-01","conditions":"Postoperative Ocular Pain After PRK Surgery","enrollment":40},{"nctId":"NCT02653391","phase":"PHASE1, PHASE2","title":"A Study Investigating the Safety, Tolerability, and Efficacy of Elamipretide Topical Ophthalmic Solution for the Treatment of Fuchs' Corneal Endothelial Dystrophy (FCED)","status":"COMPLETED","sponsor":"Stealth BioTherapeutics Inc.","startDate":"2016-02","conditions":"Fuchs' Corneal Endothelial Dystrophy (FCED)","enrollment":22},{"nctId":"NCT03414645","phase":"PHASE1, PHASE2","title":"Topical Fibrinogen-Depleted Human Platelet Lysate in Patients With Dry Eye Secondary to Graft vs. Host Disease","status":"COMPLETED","sponsor":"Cambium Bio Limited","startDate":"2018-05-01","conditions":"Dry Eye, Graft-versus-host-disease, Ocular Discomfort","enrollment":64},{"nctId":"NCT03131167","phase":"PHASE1","title":"Study of SHP639 Eye Drops in Adults With High Eye Pressure or Primary Open-angle Glaucoma","status":"COMPLETED","sponsor":"Shire","startDate":"2017-05-10","conditions":"Primary Open-angle Glaucoma (POAG), Ocular Hypertension","enrollment":63},{"nctId":"NCT00634972","phase":"PHASE4","title":"Efficient Study of ACULAR in Inhibiting Proliferative Retinopathy in Prematurity","status":"TERMINATED","sponsor":"University of South Alabama","startDate":"2005-11","conditions":"Retinopathy of Prematurity, Retinal Detachment, Blindness","enrollment":83},{"nctId":"NCT04268069","phase":"PHASE2","title":"Efficacy and Safety of PL9643 Ophthalmic Solution in Subjects With Dry Eye","status":"COMPLETED","sponsor":"ORA, Inc.","startDate":"2020-02-14","conditions":"Dry Eye Disease","enrollment":160},{"nctId":"NCT03533244","phase":"PHASE2","title":"A Study of the Response to AG-86893 in Patients With Pterygium Hyperemia","status":"COMPLETED","sponsor":"Allgenesis Biotherapeutics Inc.","startDate":"2018-10-11","conditions":"Pterygium","enrollment":64},{"nctId":"NCT03216902","phase":"PHASE2","title":"A Phase IIb Safety and Efficacy Study of DE-126 Ophthalmic Solution in Primary Open-Angle Glaucoma or Ocular Hypertension- Angel Study","status":"COMPLETED","sponsor":"Santen Inc.","startDate":"2017-07-25","conditions":"Open-angle Glaucoma, Ocular Hypertension","enrollment":241},{"nctId":"NCT02373397","phase":"NA","title":"Cacicol20® in Corneal Wound Healing and Nerve Regeneration After Phototherapeutic Keratectomy","status":"TERMINATED","sponsor":"Neil Lagali","startDate":"2015-03","conditions":"Corneal Dystrophy, Epithelial Basement Membrane, Epithelial Recurrent Erosion Dystrophy, Corneal Erosions","enrollment":40},{"nctId":"NCT03368339","phase":"PHASE2","title":"Effectiveness of PR013 Topical Ophthalmic Drops Compared to Vehicle for the Treatment of Allergic Conjunctivitis","status":"COMPLETED","sponsor":"Realm Therapeutics, Inc.","startDate":"2017-12-10","conditions":"Allergic Conjunctivitis","enrollment":96},{"nctId":"NCT03821415","phase":"PHASE2","title":"Effects of RP101 in Post-menopausal Women With Dry Eye Syndrome","status":"COMPLETED","sponsor":"Redwood Pharma AB","startDate":"2019-01-18","conditions":"Dry Eye Syndromes","enrollment":104},{"nctId":"NCT02617667","phase":"PHASE2","title":"CyclASol for the Treatment of Moderate to Severe Dry-eye Disease (DED)","status":"COMPLETED","sponsor":"Novaliq GmbH","startDate":"2016-01","conditions":"Dry Eye Syndromes","enrollment":207},{"nctId":"NCT01933464","phase":"PHASE1, PHASE2","title":"An Analysis of the Effect of Topical Cromolyn Sodium on Rosacea-associated Erythema","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2013-08","conditions":"Papulopustular Rosacea","enrollment":10},{"nctId":"NCT03615196","phase":"PHASE1","title":"Study of the Safety of USB005 in Healthy Volunteers","status":"COMPLETED","sponsor":"US Biotest, Inc.","startDate":"2018-07-25","conditions":"Healthy Volunteers","enrollment":32},{"nctId":"NCT02329743","phase":"PHASE2","title":"Efficacy and Safety of RX-10045 Ophthalmic Solution for Ocular Inflammation and Pain in Cataract Surgery","status":"COMPLETED","sponsor":"A.T. Resolve SARL","startDate":"2014-12","conditions":"Inflammation, Pain, Cataract","enrollment":256},{"nctId":"NCT02815293","phase":"PHASE3","title":"Topical Ophthalmic AGN-195263 for the Treatment of Evaporative Dry Eye","status":"TERMINATED","sponsor":"Allergan","startDate":"2016-09-30","conditions":"Dry Eye Syndromes","enrollment":36},{"nctId":"NCT02965846","phase":"PHASE3","title":"Topical Ophthalmic AGN-195263 for the Treatment of Evaporative Dry Eye","status":"TERMINATED","sponsor":"Allergan","startDate":"2016-12-13","conditions":"Dry Eye Syndromes","enrollment":43},{"nctId":"NCT01749930","phase":"PHASE3","title":"Comparing the Safety and Efficacy of BOL-303259-X Ophthalmic Solution With Timolol Maleate Ophthalmic Solution in Subjects With Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2013-01","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":420},{"nctId":"NCT01749904","phase":"PHASE3","title":"Comparing Safety and Efficacy of BOL-303259-X With Timolol Maleate in Subjects With Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2013-01-31","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":420},{"nctId":"NCT03162094","phase":"PHASE1, PHASE2","title":"Assessing the Safety and Efficacy of AVX-012 in Subjects With Mild-to-moderate Dry Eye Syndrome","status":"UNKNOWN","sponsor":"Avizorex Pharma, S.L.","startDate":"2017-04-03","conditions":"Dry Eye Syndrome","enrollment":172},{"nctId":"NCT00712400","phase":"NA","title":"Effects of Latanoprost on Choroidal Blood Flow Regulation in Human Subjects","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2005-06","conditions":"Ocular Physiology, Intraocular Pressure, Regional Blood Flow","enrollment":24},{"nctId":"NCT03066219","phase":"PHASE2","title":"Safety and Efficacy of BRM421 for Dry Eye Syndrome","status":"COMPLETED","sponsor":"BRIM Biotechnology Inc.","startDate":"2017-02-07","conditions":"Dry Eye Syndrome","enrollment":157},{"nctId":"NCT01977781","phase":"PHASE1","title":"Safety and Efficacy of Topical Tacrolimus 0.05% in the Treatment of Ocular Graft-Versus-Host Disease","status":"COMPLETED","sponsor":"Massachusetts Eye and Ear Infirmary","startDate":"2013-12","conditions":"Ocular GVHD","enrollment":40},{"nctId":"NCT01064830","phase":"PHASE2","title":"Topical Cyclosporine Suspension for the Treatment of Brittle Nails","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2010-02","conditions":"Brittle Nail Syndrome","enrollment":21},{"nctId":"NCT02420730","phase":"PHASE1","title":"Safety, Tolerability and Systemic Pharmacokinetics of AGN-232411 in Healthy Participants and Participants With Dry Eye","status":"COMPLETED","sponsor":"Allergan","startDate":"2015-06","conditions":"Healthy Volunteers, Dry Eye Syndromes","enrollment":77},{"nctId":"NCT01998802","phase":"PHASE3","title":"Phase 3 Study of EBI-005 in Dry Eye Disease","status":"COMPLETED","sponsor":"Eleven Biotherapeutics","startDate":"2014-01","conditions":"Dry Eye Disease (DED)","enrollment":670},{"nctId":"NCT02405039","phase":"PHASE3","title":"Study of EBI-005 in Dry Eye Disease (DED)","status":"UNKNOWN","sponsor":"Eleven Biotherapeutics","startDate":"2015-04","conditions":"Dry Eye","enrollment":188},{"nctId":"NCT02051023","phase":"PHASE3","title":"Efficacy and Safety of Fluorometholone (FML) in Dry Eye Disease (Keratoconjunctivitis Sicca)","status":"COMPLETED","sponsor":"Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA","startDate":"2014-02","conditions":"Dry Eye","enrollment":41},{"nctId":"NCT02170662","phase":"PHASE2","title":"Topical Bimatoprost Effect on Androgen Dependent Hair Follicles","status":"COMPLETED","sponsor":"Duke University","startDate":"2009-11","conditions":"Male Pattern Hair Loss, Androgenetic Alopecia","enrollment":33},{"nctId":"NCT02082899","phase":"PHASE2","title":"A Single Center Study for the Treatment of Moderate to Severe Allergic Conjunctivitis (EBI-005-AC-1)","status":"COMPLETED","sponsor":"Eleven Biotherapeutics","startDate":"2014-02","conditions":"Allergic Conjunctivitis","enrollment":150},{"nctId":"NCT02127463","phase":"PHASE2, PHASE3","title":"Phase II/III Study of the Efficacy and Safety of MacuCLEAR MC-1101 in Treating DryAge-Related Macular Degeneration","status":"UNKNOWN","sponsor":"MacuCLEAR, Inc.","startDate":"2014-04","conditions":"Non-Exudative Age Related Macular Degeneration","enrollment":60},{"nctId":"NCT01922128","phase":"PHASE1","title":"Safety Study of a Topical Treatment for Dry Age Related Macular Degeneration","status":"COMPLETED","sponsor":"MacuCLEAR, Inc.","startDate":"2013-09","conditions":"Nonexudative Age-related Macular Degeneration","enrollment":20},{"nctId":"NCT00105534","phase":"PHASE3","title":"Evaluation of Clinical and Microbial Efficacy and Safety of AzaSite Compared to Vehicle for Bacterial Conjunctivitis (C-01-401-003)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2004-07","conditions":"Bacterial Conjunctivitis","enrollment":685},{"nctId":"NCT01426854","phase":"PHASE3","title":"Nepafenac Compared to Placebo for Ocular Pain and Inflammation","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2011-07","conditions":"Cataract","enrollment":260},{"nctId":"NCT01135511","phase":"PHASE2","title":"A Phase II, Dose Ranging Study Of CP-690,550 Eye Drops In Patients With Dry Eye Disease","status":"COMPLETED","sponsor":"Pfizer","startDate":"2010-07","conditions":"Dry Eye Syndromes","enrollment":285},{"nctId":"NCT00423007","phase":"PHASE3","title":"Efficacy and Safety of Topical Bromfenac Ophthalmic Solution vs. Placebo in Subjects With Allergic Conjunctivitis","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2006-11","conditions":"Allergic Conjunctivitis","enrollment":90},{"nctId":"NCT00198445","phase":"PHASE3","title":"Safety and Efficacy Study of Topical Bromfenac Versus Placebo to Treat Ocular Inflammation After Cataract Surgery","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2003-05","conditions":"Postoperative Complications, Cataract","enrollment":527},{"nctId":"NCT01276223","phase":"PHASE2","title":"Evaluation of Anti-Inflammatory Treatment in Dry Eye Patients","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2011-02","conditions":"Dry Eye Disease","enrollment":722},{"nctId":"NCT01279083","phase":"PHASE1, PHASE2","title":"Safety and Efficacy Trial to Treat Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Santen Inc.","startDate":"2011-01","conditions":"Open-angle Glaucoma, Ocular Hypertension","enrollment":147},{"nctId":"NCT01123785","phase":"PHASE1, PHASE2","title":"A Dose-Escalation Study Designed to Evaluate the Tolerability, Safety, Pharmacokinetics (PK), and Efficacy of Chronic Topical Ocular Application of INO-8875 in Adults With Ocular Hypertension or Primary Open-Angle Glaucoma","status":"COMPLETED","sponsor":"Inotek Pharmaceuticals Corporation","startDate":"2010-05","conditions":"Glaucoma, Ocular Hypertension","enrollment":144}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":97,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Vehicle"],"phase":"phase_3","status":"active","brandName":"Vehicle topical ocular, eye drops","genericName":"Vehicle topical ocular, eye drops","companyName":"Novaliq GmbH","companyId":"novaliq-gmbh","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Vehicle topical ocular eye drops act as a carrier for other medications, allowing them to be delivered directly to the eye. Used for Treatment of dry eye disease.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":2,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}